CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma

Hsin-Tzu Hsieh; Hsi‐Chien Huang; Chieh-Wei Chung; Cheng-Chin Chiang; Tiffaney Hsia; Hsin-Fang Wu; Rui-Lin Huang; Chi‐Shiun Chiang; Jane Wang; Tsai‐Te Lu; Yunching Chen

doi:10.1016/j.jconrel.2022.10.047

JOURNAL ARTICLE

CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma

Hsin-Tzu Hsieh Hsi‐Chien Huang Chieh-Wei Chung Cheng-Chin Chiang Tiffaney Hsia Hsin-Fang Wu Rui-Lin Huang Chi‐Shiun Chiang Jane Wang Tsai‐Te Lu Yunching Chen

Year: 2022 Journal: Journal of Controlled Release Vol: 352 Pages: 920-930 Publisher: Elsevier BV

DOI: 10.1016/j.jconrel.2022.10.047

Get Full-Text PDF Get Analytical Report

Keywords:

Immunotherapy Cancer research Tumor microenvironment CXCR4 Cytotoxic T cell Nitric oxide Immune system Chemistry Medicine Immunology Chemokine Tumor cells Internal medicine In vitro Biochemistry

Metrics

Cited By

4.77

FWCI (Field Weighted Citation Impact)

Refs

0.93

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Nanoplatforms for cancer theranostics

Physical Sciences → Engineering → Biomedical Engineering

RNA Interference and Gene Delivery

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

Immunotherapy and Immune Responses

Life Sciences → Immunology and Microbiology → Immunology

CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma

Metrics

Citation History

Topics

Related Documents

PD-L1 siRNA–hyaluronic acid conjugate for dual-targeted cancer immunotherapy

PD-L1 Targeted Immunoliposomes with PD-L1 siRNA and HDAC Inhibitor for Anti-Lung Cancer Immunotherapy

Targeted Nanoparticles Deliver siRNA to Melanoma

Targeted Nanoparticles Deliver siRNA to Melanoma

Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles